The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark,

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs,

In the lawsuit, AG Gentner Drummond outlined 200 individual prescription claims that were reimbursed below acquisition cost to 15 Oklahoma pharmacies.

At least one Woodward pharmacist is celebrating an action by Oklahoma Attorney General Gentner Drummond that could turn the tide for area pharmacists, some who are struggling to stay in

Attorney General Gentner Drummond sued CVS Caremark in an Oklahoma administrative court alleging that the company is under reimbursing pharmacies for prescription drugs.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without many pharmacy options.

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for prescription drugs.

Pharmacies across Oklahoma say they are losing hundreds of thousands of dollars because they say a company, CVS Caremark, is supposed to reimburse them for prescriptions and isn't holding up their end of the bargain.

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market. Meanwhile, the price patients pay for drugs has increased nearly 300% in the last 30 years, according to Peterson-KFF Health System Tracker.

Edward Jones, a financial services firm, upgraded CVS Health (NYSE:CVS) stock from Hold to Buy. The upgrade comes as the stock, which InvestingPro analysis shows is currently undervalued, has posted a strong 28.